Atim-3 and Flt-3L would be released at the tumor site in response to ROS; the released Flt-3L would promote the accumulation and proliferation of DCs; and TIM-3 blocked the phenotype of tolerant DC, promoted the infiltration and activation of T lymphocytes, and enhanced the anti-tumor immune response. The gene discussed is HAVCR2; the disease is neoplasm.